

Supporting Information for DOI: 10.1055/a-1957-4343 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany



Tf₂O-Promoted Morgan–Walls Reaction: from A Flexible Approach to Functionalized Phenanthridines and Quinazolines to the Short and Divergent Total Syntheses of Alkaloids

Xiao-Yu Su, Pei-Qiang Huang*

Table of Contents

1. Ge	eneral Methods	.2
1.1.	Table S1. The structure of all amide substrates 11	.3
1.2.	Synthesis of amides 11a-11e, 11g-11q, 11s-11w, 11y-11z	.4
1.3.	Synthesis of amides 11f, 11x, 11r, 11aa	10
1.4.	General procedure for the synthesis of aniline derivatives v	ia
Suzuki coupling reaction12		12
References		13
2. Copies of ¹ H and ¹³ C NMR spectra of new compounds14		14

1. General Methods

NMR spectra were recorded on a Bruker Avance 400 MHz or 500 MHz instrument and were calibrated using residual undeuterated solvent (CHCl₃ at 7.26 ppm ¹H NMR, 77 ppm ¹³C NMR) [multiplicity, coupling constant (s) J (Hz), relative integral], where multiplicity is defined as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, or combinations thereof. IR spectra were recorded on a Nicolet iS50 FT-IR spectrometer using film KBr pellet techniques. High-resolution mass spectrometry (HRMS) was performed using positive electrospray ionization (ESI+) on a Single Quadrupole Exactive LC/MS and orbitrap Mass Detector. Silica gel (300 – 400 mesh) was used for flash column chromatography, eluting (unless otherwise stated) with EtOAc/n-hexane mixture. Solvent compositions were mixed in v/v as specified. Trifluoromethanesulfonic anhydride (Tf₂O) was distilled over phosphorous pentoxide and was stored for no more than a week before use. Dichloromethane (DCM) was distilled over calcium hydride under N₂ atmosphere. All other commercially available compounds were used as received.



1.1. Table S1. The structure of all amide substrates 11

1.2. Synthesis of amides 11a – 11e, 11g – 11q, 11s – 11w, 11y – 11z

Amides **11a** – **11e**, **11g** – **11q**, **11s** – **11w**, **11y** – **11z** were prepared by a known protocol.¹⁻ 8

N-([1,1-Biphenyl]-2-yl)acetamide (11a)¹

Mp 121–123 °C (lit.¹ mp 119.8–120.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 2.05 (s, 3H), 7.14 – 7.31 (m, 2H), 7.37 – 7.44 (m, 1H), 7.46 (m, 4H), 7.52 (t, *J* = 7.4 Hz, 2H), 8.29 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 24.6, 121.6, 124.4, 127.9, 128.4, 129.1, 129.2, 130.0, 134.6, 138.1, 168.2 ppm.

N-([1,1'-Biphenyl]-2-yl)isobutyramide (11b)²

Mp 134.3–134.7 °C (lit.³ mp 135.0–137.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 1.10 (d, J = 6.9 Hz, 6H), 2.25 – 2.40 (m, 1H), 7.17 (d, J = 7.4 Hz, 2H), 7.25 (d, J = 9.5 Hz, 2H), 7.32 – 7.53 (m, 6H), 8.32 (d, J = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 19.3, 36.7, 121.3, 124.1, 128.0, 128.4, 129.0, 129.3, 129.9, 134.9, 138.1, 174.8 ppm.

N-([1,1-Biphenyl]-2-yl)pivalamide (11c)²

Mp 66.5–66.7 °C (lit.³ mp 66.0–68.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 1.09 (s, 9H), 7.15 (t, *J* = 7.5 Hz, 1H), 7.20 – 7.28 (m, 1H), 7.32 – 7.54 (m, 7H), 8.36 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 27.3, 39.8, 120.9, 123.9, 128.0, 128.5, 129.0, 129.3, 129.7, 132.2, 135.1, 138.1, 176.3 ppm.

N-([1,1-Biphenyl]-2-yl)cyclopropanecarboxamide (11d)

Mp 115.5-115.9 °C. IR (KBr): 3228, 1655, 1583, 1518, 1493, 1479, 1436, 1390, 1300, 1280, 1197, 1179, 1099, 1030, 1010, 956, 754, 701 cm⁻¹.¹H NMR (400 MHz, CDCl₃): δ 0.70 – 0.80 (m, 2H), 0.98 – 1.06 (m, 2H), 1.24 (s, 1H), 7.15 (t, *J* = 7.5 Hz, 1H), 7.19 – 7.28 (m, 1H), 7.30 – 7.46 (m, 5H), 7.49 (t, *J* = 7.2 Hz, 2H), 8.32 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 7.8, 15.8, 121.2, 123.9, 127.9, 128.4, 129.1, 129.3, 130.0, 134.9, 138.2, 171.7 ppm. HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₆H₁₅NO: 238.1226; found: 238.1228.

N-([1,1-Biphenyl]-2-yl)cyclopentanecarboxamide (11e)

Mp 119.0–119.3 °C. IR (KBr): 3228, 2958, 1647, 1599, 1583, 1530, 1479, 1448, 1434, 1383, 1272, 1239, 1009, 775, 748, 699 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.46 –

1.60 (m, 2H), 1.62 – 1.85 (m, 7H), 2.48 (p, J = 8.0 Hz, 1H), 7.08 – 7.27 (m, 3H), 7.31 – 7.55 (m, 6H), 8.31 (d, J = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 25.8, 30.1, 46.9, 121.3, 124.0, 127.9, 128.4, 129.0, 129.3, 129.9, 132.0, 135.0, 138.2, 174.2 ppm. HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₉NO: 266.1539; found: 266.1541.

N-([1,1-Biphenyl]-2-yl)benzamide (11g)⁴

Mp 89.2–89.6 °C (lit.⁴ mp 91.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.27 (t, *J* = 7.5 Hz, 1H), 7.32 – 7.39 (m, 1H), 7.42 (t, *J* = 7.6 Hz, 2H), 7.45 – 7.60 (m, 7H), 7.66 (d, *J* = 7.2 Hz, 2H), 8.10 (s, 1H), 8.58 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): 121.2, 124.3, 126.7, 128.1, 128.5, 128.6, 129.1, 129.2, 129.9, 131.6, 132.4, 134.6, 134.8, 138.0, 164.9 ppm.

N-([1,1-Biphenyl]-2-yl)-4-methylbenzamide (11h)⁵

Mp 110.0–110.6 °C (lit.⁵ mp 108.0–109.0 °C) . ¹H NMR (400 MHz, CDCl₃): δ 2.36 (s, 3H), 7.14 – 7.23 (m, 3H), 7.29 (dd, J = 7.6, 1.7 Hz, 1H), 7.37 – 7.55 (m, 8H), 7.98 (s, 1H), 8.53 (d, J = 8.1 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 24.6, 121.6, 124.4, 127.9, 128.4, 129.1, 129.2, 130.0, 134.6, 138.1, 168.2 ppm.

N-([1,1-Biphenyl]-2-yl)-2-methylbenzamide (11i)⁶

Mp 93.0–93.5 °C (lit.⁶ mp 90.0–90.1 °C). ¹H NMR (400 MHz, CDCl₃): δ 2.45 (s, 3H), 7.16 – 7.36 (m, 6H), 7.41 – 7.53 (m, 6H), 7.56 (s, 1H), 8.52 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 19.8, 121.6, 124.6, 125.8, 126.4, 128.0, 128.5, 129.0, 129.2, 130.1, 130.2, 131.3, 132.8, 134.8, 136.2, 136.5, 138.1, 167.8 ppm.

N-([1,1-Biphenyl]-2-yl)-4-methoxybenzamide (11j)⁵

Mp 133.3–134.3 °C (lit.⁵ mp 131.0–132.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 3.82 (s, 3H), 6.86 (d, *J* = 8.5 Hz, 2H), 7.20 (t, *J* = 7.5 Hz, 1H), 7.29 (d, *J* = 7.5 Hz, 1H), 7.38 – 7.59 (m, 8H), 7.92 (s, 1H), 8.52 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 55.4, 113.9, 121.0, 124.1, 127.0, 128.1, 128.5, 128.6, 129.2, 129.3, 129.9, 132.1, 135.1, 138.1, 162.3, 164.5 ppm.

N-([1,1'-Biphenyl]-2-yl)-3,5-dimethylbenzamide (11k)

Mp 106.6–107.1 °C. IR (KBr): 3425, 2918, 1678, 1605, 1583, 1519, 1493, 1447, 1437, 1382, 1316, 788, 756, 704, 680 cm⁻¹.¹H NMR (400 MHz, CDCl₃): δ 2.33 (s, 6H), 7.14

(s, 1H), 7.21 - 7.32 (m, 3H), 7.35 (dd, J = 7.6, 1.6 Hz, 1H), 7.43 - 7.53 (m, 4H), 7.53 - 7.61 (m, 2H), 8.02 (s, 1H), 8.58 (d, J = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 21.2, 120.9, 124.2, 124.6, 128.1, 128.6, 129.1, 129.5, 129.8, 132.2, 133.3, 134.8, 135.1, 138.1, 138.4, 165.3 ppm. HRMS (ESI): m/z [M+H]⁺ calcd for C₂₁H₁₉NO: 302.1539; found: 302.1540.

N-([1,1'-Biphenyl]-2-yl)-2,6-dichlorobenzamide (111)

Mp 178.0–178.6 °C. IR (KBr): 3215, 1958, 1647, 1517, 1478, 1451, 1430, 1295, 1192, 1150, 1086, 1008, 914, 799, 787, 775, 750, 741, 702, 693 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 7.22 – 7.37 (m, 6H), 7.40 (t, *J* = 6.8 Hz, 1H), 7.43 – 7.55 (m, 5H), 8.47 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 122.4, 125.3, 128.0, 128.1, 128.5, 128.9, 129.6, 130.4, 130.8, 132.2, 133.0, 133.9, 135.9, 137.6, 162.6 ppm. HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₃Cl₂NO: 342.0447; found: 342.0448.

N-(4'-Methoxy-[1,1'-biphenyl]-2-yl)-4-methylbenzamide (11m)⁷

Mp 121.7–122.4 °C. ¹H NMR (400 MHz, CDCl₃): δ 2.37 (s, 3H), 3.87 (s, 3H), 7.03 (d, J = 8.6 Hz, 2H), 7.18 (t, J = 8.4 Hz, 3H), 7.26 – 7.43 (m, 4H), 7.52 (d, J = 8.1 Hz, 2H), 8.00 (s, 1H), 8.51 (d, J = 8.1 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 21.4, 55.4, 114.6, 121.0, 124.1, 126.8, 128.3, 129.4, 130.1, 130.2, 130.5, 131.9, 132.0, 135.2, 142.2, 159.4 ppm.

N-(4'-Methoxy-[1,1'-biphenyl]-2-yl)-2-methylbenzamide (11n)

Mp 113.0–113.2 °C. IR (KBr): 3409, 3300, 1678, 1611, 1582, 1516, 1443, 1302, 1268, 1246, 1177, 1035, 833, 804, 759, 741 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 2.42 (s, 3H), 3.83 (s, 3H), 6.97 (d, *J* = 8.0 Hz, 2H), 7.11 – 7.20 (m, 2H), 7.23 – 7.35 (m, 6H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.53 (s, 1H), 8.47 (d, *J* = 8.1 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 19.9, 55.3, 114.5, 121.4, 124.5, 125.9, 126.4, 128.2, 130.2, 130.2, 130.3, 130.4, 131.3, 132.3, 135.1, 136.3, 136.5, 159.4 ppm. HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₂₁H₁₉NO₂: 318.1489; found: 318.1489.

N-(4-Fluoro-[1,1-biphenyl]-2-yl)-4-methylbenzamide (110)

Mp 106.0–107.6 °C. IR (KBr): 3216, 2921, 1682, 1597, 1529, 1493, 1462, 1446, 1424, 1296, 1281, 1252, 1188, 1161, 1117, 1081, 1010, 975, 870, 816, 767, 744, 704, 612 cm⁻

¹. ¹H NMR (400 MHz, CDCl₃): δ 2.40 (s, 3H), 6.93 (td, J = 8.2, 2.7 Hz, 1H), 7.19 – 7.27 (m, 3H), 7.41 – 7.46 (m, 2H), 7.50 (d, J = 7.8 Hz, 3H), 7.52 – 7.58 (m, 2H), 8.07 (s, 1H), 8.47 (dd, J = 11.4, 2.7 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 21.4, 107.8, 108.1, 110.6, 110.8, 126.8, 127.6, 127.6, 128.3, 128.9, 129.1, 129.4, 129.5, 130.8, 130.9, 131.6, 136.4, 136.5, 137.3, 142.6, 161.5, 163.5, 164.8 ppm. HRMS (ESI): m/z [M+H]⁺ calcd for C₂₀H₁₆FNO: 306.1289; found: 306.1291.

N-(4-Fluoro-[1,1'-biphenyl]-2-yl)isobutyramide (11p)

Mp 109.6–109.9 °C. IR (KBr): 3216, 2966, 1522, 1500, 1478, 1466, 1448, 1096, 856, 819, 765, 701 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.12 (d, *J* = 6.9 Hz, 6H), 2.27 – 2.42 (m, 1H), 6.88 (td, *J* = 8.2, 2.7 Hz, 1H), 7.20 (dd, *J* = 8.5, 6.3 Hz, 1H), 7.29 (s, 2H), 7.32 – 7.40 (m, 2H), 7.41 – 7.49 (m, 1H), 7.49 – 7.57 (m, 2H), 8.26 (dd, *J* = 11.4, 2.7 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 19.2, 36.7, 108.0, 108.2, 110.5, 110.6, 127.4, 128.2, 129.2, 129.4, 130.8, 130.8, 136.2, 136.3, 137.3, 161.4, 163.4, 174.9 ppm. HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₆H₁₆FNO: 258.1289; found: 258.1290.

Ethyl 4-([1,1'-biphenyl]-2-ylamino)-4-oxobutanoate (11q)

Mp 81.1–81.2 °C. IR (KBr): 3293, 2981, 1732, 1690, 1585, 1522, 1495, 1448, 1437, 1374, 1349, 1322, 1301, 1280, 1162, 1023, 1010, 757, 703 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 1.23 (t, *J* = 7.1 Hz, 3H), 2.46 (t, *J* = 6.8 Hz, 2H), 2.64 (t, *J* = 6.7 Hz, 2H), 4.10 (q, *J* = 7.1 Hz, 2H), 7.16 (t, *J* = 7.5 Hz, 1H), 7.20 – 7.27 (m, 1H), 7.29 – 7.44 (m, 5H), 7.47 (t, *J* = 7.4 Hz, 2H), 8.23 (d, *J* = 8.1 Hz, 1H) ppm. ¹³C NMR (125 MHz, CDCl₃): δ 14.1, 29.1, 31.8, 60.6, 76.7, 77.0, 77.3, 121.7, 124.3, 127.8, 128.2, 128.9, 129.2, 130.0, 132.3, 134.5, 138.0, 169.5, 172.6. HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₈H₁₉NO₃: 298.1438; found: 298.1440.

N-([1,1'-Biphenyl]-2-yl)-4-(*tert*-butyl)benzamide (11s)⁵

Mp 161.0–162.7 °C (lit.⁵ 160.0–161.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 1.31 (s, 9H), 7.21 (td, *J* = 7.4, 1.2 Hz, 1H), 7.27 – 7.31 (m, 1H), 7.37 – 7.49 (m, 6H), 7.50 – 7.56 (m, 4H), 8.00 (s, 1H), 8.56 (dd, *J* = 8.3, 1.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 31.1, 34.9, 121.0, 124.2, 125.7, 126.7, 128.2, 128.6, 129.2, 129.4, 130.0, 131.9, 155.3, 164.8 ppm.

N-([1,1-Biphenyl]-2-yl)-4-chlorobenzamide (11t)⁵

Mp 105.9–108.0 °C (lit.⁵ 104.0–105.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.23 (t, *J* = 7.5 Hz, 1H), 7.31 (dd, *J* = 7.6, 1.4 Hz, 1H), 7.36 (d, *J* = 8.5 Hz, 2H), 7.44 (t, *J* = 6.2 Hz, 4H), 7.52 (t, *J* = 7.2 Hz, 4H), 7.93 (s, 1H), 8.49 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 121.1, 124.6, 128.2, 128.3, 128.6, 129.0, 129.2, 129.3, 130.0, 132.4, 133.1, 134.6, 137.9, 163.9 ppm.

N-([1,1-Biphenyl]-2-yl)-4-fluorobenzamide (11u)⁸

Mp 128.5–129.8 °C . ¹H NMR (400 MHz, CDCl₃): δ 7.04 (t, *J* = 8.1 Hz, 2H), 7.22 (t, *J* = 7.4 Hz, 1H), 7.30 (d, *J* = 7.5 Hz, 1H), 7.38 – 7.47 (m, 4H), 7.51 (t, *J* = 7.0 Hz, 2H), 7.55 – 7.63 (m, 2H), 7.93 (s, 1H), 8.46 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 115.6, 115.9, 121.2, 124.5, 128.2, 128.6, 129.1, 129.2, 129.3, 130.0, 130.9, 130.9, 132.4, 134.7, 138.0, 163.5, 163.9, 166.0 ppm.

N-([1,1-Biphenyl]-2-yl)-4-(trifluoromethyl)benzamide (11v)⁵

Mp 130.0 –130.8 °C (lit.⁵ 127.0–128.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.04 (t, *J* = 8.0 Hz, 2H), 7.22 (m, 1H), 7.30 (d, *J* = 7.5 Hz, 1H), 7.38 – 7.47 (m, 4H), 7.51 (t, *J* = 7.0 Hz, 2H), 7.55 – 7.63 (m, 2H), 7.93 (s, 1H), 8.46 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): 121.2, 124.8, 125.8, 127.3, 128.4, 128.7, 129.3, 130.0, 132.6, 134.5, 137.9, 163.6 ppm.

N-([1,1-Biphenyl]-2-yl)-4-nitrobenzamide (11w)⁵

Mp 109.5–110.0 °C (lit.⁵ 109.0–110.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.26 (t, *J* = 7.4 Hz, 1H), 7.33 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.39 – 7.57 (m, 6H), 7.74 (d, *J* = 8.7 Hz, 2H), 8.03 (s, 1H), 8.18 – 8.25 (m, 2H), 8.44 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 121.3, 123.9, 125.1, 127.9, 128.4, 128.6, 129.2, 129.3, 130.1, 132.8, 134.1, 137.7, 140.2, 149.6, 162.9 ppm.

Methyl 4-([1,1'-biphenyl]-2-ylcarbamoyl)benzoate (11y)

Mp 182.3–182.0 °C. IR (KBr): 3242, 1729, 1642, 1530, 1280, 1109, 868, 750, 741, 721, 704 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 3.93 (s, 3H), 7.23 (d, *J* = 7.4 Hz, 1H), 7.32 (d, *J* = 7.7, 1.7 Hz, 1H), 7.40 – 7.56 (m, 6H), 7.65 (d, *J* = 8.4 Hz, 2H), 8.04 (t, *J* = 8.8 Hz, 3H), 8.51 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 52.4, 121.1,

124.7, 126.8, 128.3, 128.6, 129.3, 129.3, 130.0, 132.5, 132.9, 134.6, 137.8, 138.6, 164.0, 166.1 ppm. HRMS (ESI): m/z [M+H]⁺ calcd for C₂₁H₁₇NO₃: 332.1281; found: 332.1281.

N-([1,1-Biphenyl]-2-yl)-2-naphthamide (11z)

Mp 90.0–98.9 °C. IR (KBr): 3423, 3358, 2918, 1667, 1617, 1583, 1520, 1493, 1483, 1446, 1435, 1385, 1307, 1131, 1091, 1009, 773, 750, 703 cm^{-1.1}H NMR (400 MHz, CDCl₃): δ 7.23 (d, *J* = 7.4 Hz, 1H), 7.30 – 7.36 (m, 1H), 7.44 – 7.59 (m, 8H), 7.67 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.83 (dd, *J* = 16.1, 8.1 Hz, 3H), 8.07 (s, 1H), 8.15 (s, 1H), 8.59 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 115.6, 118.6, 121.2, 123.2, 124.4, 126.8, 127.1, 127.4, 127.6, 127.7, 127.8, 128.2, 128.4, 128.6, 128.6, 128.7, 128.9, 129.0, 129.2, 129.4, 129.9, 130.4, 131.9, 132.4, 132.5, 134.7, 135.0, 138.1, 139.5, 143.4, 165.0 ppm. HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₂₃H₁₇NO: 324.1383; found: 324.1384.

1.3. Synthesis of amides 11f, 11x, 11r, and 11aa

Amides 11f, 11x, 11r and 11aa were prepared by a known protocol. 9-10

N-([1,1-Biphenyl]-2-yl)cyclohexanecarboxamide (11f)

Mp 133.3–134.1 °C. IR (KBr): 3250, 2928, 2850, 1655, 1518, 1493, 1447, 1436, 1383, 1276, 1130, 1075, 1031, 1009, 747, 701 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.11 – 1.28 (m, 3H), 1.28 – 1.40 (m, 2H), 1.63 (d, *J* = 10.0 Hz, 1H), 1.71 – 1.76 (m, 3H), 1.80 (d, *J* = 9.4 Hz, 2H), 2.00 – 2.10 (m, 1H), 7.13 – 7.27 (m, 3H), 7.33 – 7.39 (m, 3H), 7.42 (t, *J* = 7.4 Hz, 1H), 7.49 (t, *J* = 7.5 Hz, 2H), 8.30 (d, *J* = 8.3 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 25.52, 25.62, 29.39, 46.31, 121.53, 124.07, 127.94, 128.36, 128.98, 129.29, 129.89, 132.22, 134.84, 138.16, 173.98 ppm. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₉H₂₁NO: 280.1696; found: 280.1697.

N-([1,1'-Biphenyl]-2-yl)-5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamide (11r) IR (KBr): 3433, 3358, 2954, 2868, 1686, 1615, 1584, 1509, 1492, 1474, 1445, 1414, 1390, 1300, 1284, 1266, 1157, 1130, 1046, 1009, 804, 752, 704, 587 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.09 (s, 6H), 1.54 – 1.63 (m, 2H), 1.63 – 1.75 (m, 2H), 2.13 (s, 3H), 2.29 (s, 3H), 3.83 (t, *J* = 6.1 Hz, 2H), 6.57 (s, 1H), 6.65 (d, *J* = 7.5 Hz, 1H), 6.98 (d, *J* = 7.4 Hz, 1H), 7.16 (t, *J* = 7.4 Hz, 1H), 7.21 – 7.28 (m, 1H), 7.33 – 7.43 (m, 4H), 7.47 (t, *J* = 7.3 Hz, 3H), 8.35 (d, *J* = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 15.8, 21.4, 25.0, 25.2, 37.7, 42.9, 67.8, 111.9, 120.7, 120.9, 123.5, 123.9, 128.1, 128.5, 129.0, 129.3, 129.7, 130.2, 132.2, 135.0, 136.4, 138.1, 156.8, 175.3 ppm. HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₂₇H₃₁NO₂: 402.2428; found: 402.2430.

N-([1,1'-Biphenyl]-2-yl)-4-cyanobenzamide (11x)⁹

Mp 134.0–134.5 °C (lit.⁹ mp 132.0–134.0 °C). ¹H NMR (400 MHz, CDCl₃): δ 7.30 (d, J = 7.6 Hz, 2H), 7.35 (dd, J = 7.7, 1.7 Hz, 1H), 7.42 – 7.52 (m, 4H), 7.55 (dd, J = 8.0, 6.3 Hz, 2H), 7.71 (s, 4H), 7.99 (s, 1H), 8.50 (d, J = 8.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 115.3, 117.8, 121.2, 125.0, 127.4, 128.4, 128.7, 129.3, 129.3, 130.1, 132.6, 134.2, 137.7, 138.6, 163.1 ppm.

N-([1,1'-Biphenyl]-2-yl)benzo[*b*]thiophene-2-carboxamide (11aa)¹⁰

Mp 141.1–141.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.23 (dd, J = 7.4, 1.2 Hz, 1H), 7.33 (dd, J = 7.6, 1.7 Hz, 1H), 7.35 – 7.61 (m, 9H), 7.74 – 7.86 (m, 2H), 7.98 (s, 1H), 8.51 (d, J = 8.1 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 121.0, 122.7, 124.6, 125.0, 125.1, 125.4, 126.5, 128.3, 128.7, 129.3, 129.4, 130.0, 132.1, 134.5, 137.8, 138.8, 139.0, 141.0, 159.9 ppm.

1.4. General procedure for the synthesis of aniline derivatives via Suzuki coupling reaction¹¹

2-(Benzo[*d***][1,3]dioxol-5-yl)aniline (14a)**¹²: A suspension of 2-bromoaniline (16a, 1.7203 g, 10.0 mmol), 1,3-benzodioxole-5-boronic acid (15, 2.4740 g, 15.0 mmol) and Pd(OAc)₂ (5.6 mg, 2.5 mol%) in water (20 mL) was stirred at 100 °C for 30 min. The mixture was extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (EA/PE = 1: 10) to afford **14a** (2.0 g, 94%). ¹H NMR (400 MHz, CDCl₃): δ 6.00 (s, 2H), 6.72 – 6.84 (m, 2H), 6.86 – 6.96 (m, 3H), 7.06 – 7.18 (m, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 101.1, 108.6, 109.6, 115.5, 118.6, 122.4, 127.3, 128.3, 130.4, 133.3, 143.6, 146.7, 147.9 ppm. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₃H₁₁NO₂: 214.0863; found: 214.0860.

Aniline derivatives **14b-14c** were prepared by replacing 2-bromoaniline with 2-bromo-*N*-methylaniline (**16b**) and 5-(benzyloxy)-2-bromoaniline (**16c**), respectively.

2-(Benzo[*d*][**1,3**]**dioxol-5-yl)-5-(benzyloxy)aniline** (**14b**): 90% yield. white solid. Mp 129.9–130 °C. IR (KBr): 3445, 2950, 1645, 1481, 1416, 1111, 1019, 648 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 5.08 (s, 2H), 6.01 (s, 2H), 6.41 (d, *J* = 2.4 Hz, 1H), 6.48 (dd, *J* = 8.4, 2.5 Hz, 1H), 6.91 (dd, *J* = 13.5, 1.1 Hz, 3H), 7.03 (d, *J* = 8.4 Hz, 1H), 7.32 – 7.52 (m, 5H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 69.9, 101.0, 102.0, 105.0, 108.6, 109.8, 122.4, 127.4, 127.9, 128.6, 131.2, 133.1, 137.2, 144.7, 146.5, 147.9, 159.2 ppm. HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₂₀H₁₇NO₃: 320.1281; found: 320.1279.

2-(Benzo[*d*][1,3]dioxol-5-yl)-N-methylaniline (14c): 94% yield. IR (KBr): 3420, 2918, 1599, 1513, 1477, 1459, 1429, 1420, 1319, 1292, 1169, 1105, 1075, 1038, 1018, 741 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 2.79 (s, 3H), 3.95 (s, 1H), 5.98 (s, 2H), 6.66 (d, *J* = 8.1 Hz, 1H), 6.73 (td, *J* = 7.4, 1.0 Hz, 1H), 6.81 – 6.91 (m, 3H), 7.05 (dd, *J* = 7.4, 1.6 Hz, 1H), 7.20 – 7.28 (m, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 30.7, 101.0, 108.7, 109.7, 109.9, 116.7, 122.6, 127.2, 128.6, 130.0, 133.2, 146.3, 146.7, 147.9 ppm. HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₄H₁₃NO₂: 228.1019; found: 228.1016.

References

- 1. Bjørsvik, H.-R.; Elumalai, V. Eur. J. Org. Chem. 2016, 5474.
- Lv, J.; Chen, X.; Xue, X.-S.; Zhao, B.; Liang, Y.; Wang, M.; Jin, L.; Yuan, Y.; Han,
 Y.; Zhao, Y.; Lu, Y.; Zhao, J.; Sun, W.-Y.; Houk, K. N.; Shi, Z. *Nature* 2019, 575, 336.
- 3. Haridharan, R.; Muralirajan, K.; Cheng, C.-H. Adv. Synth. Catal. 2015, 357, 366.
- Tsang, W. C. P.; Munday, R. H.; Brasche, G.; Zheng, N.; Buchwald, S. L. J. Org. Chem. 2008, 73, 7603.
- Bowman, W. R.; Lyon, J. E.; Pritchard, G. J. ARKIVOC 2012, part vii, 210. DOI: 10.3998/ark.5550190.0013.714
- 6. Kumar, P.; Pathak, P. K.; Kushwaha, B. S. Asian J. Chem. 2006, 18, 1055.
- 7. Lu, R.; Cao, L.; Guan, H.; Liu, L. J. Am. Chem. Soc. 2019, 141, 6318.
- 8. Sharma, P.; Jain, N. Adv. Synth. Catal. 2018, 360, 1932.
- 9. Lion, C.; Boukou-Poba, J. P.; Charvy, C. Bull. Soc. Chim. Belg. 1989, 98, 557.
- Jung, Y. S.; Kim, P. H.; Han, S. B.; Achary, R.; Kim, M. H.; Lee, J. G.; Shin, J. S. KR2015025531A, 2015.
- Chen, J.; Tang, B.; Liu, X.; Lv, G.; Shi, Y.; Huang, T.; Xing, H.; Guo, X.; Hai, L.;
 Wu, Y. Org. Chem. Front. 2020, 7, 2944.
- 12. Guo, W.; Li, S.; Tang, L.; Li, M.; Wen, L.; Chen, C. Org. Lett., 2015, 17, 1232.

2. Copies of ¹H and ¹³C NMR spectra of new compounds

(1) Compound **11d**



(2) Compound 11e



(3) Compound 11f



(4) Compound 11k



(5) Compound 111



(6) Compound 11n



(7) Compound **110**



(8) Compound 11p



(9) Compound 11q



(10) Compound **11r**



(11) Compound **11y**



(12) Compound **11z**



(13) Compound 1a



(14) Compound 1b



(15) Compound 1c



(16) Compound 1d



(17) Compound 1e





(19) Compound 1g



(20) Compound 1h



(21) Compound 1i



(22) Compound 1j



(23) Compound 1k



(24) Compound 11



(25) Compound 1m



(26) Compound 1n



(27) Compound 10



(28) Compound 1p





(30) Compound 1r



43

(31) Compound 13a



(32) Compound 13b



(33) Compound 13c



(34) Compound 13d



(35) Compound 13e



(36) Compound 1s



(37) Compound 1t



(38) Compound 1u





(39) Compound 1v



f1 (ppm)

(40) Compound 1w



(41) Compound 1x



(42) Compound 1y



(43) Compound 1z



56

(44) Compound 1aa



(45) Trisphaeridine (4)





(47) Compound **17**



(48) Compound 16b





(50) Compound 6a



(51) Compound 6b



(52) Compound 6c



(53) Compound 6d



66

(54) *N*-methylcrinasiadine (8)

